Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV
infection. However, PBL can also be seen in patients with other immunodeficiencies as well …

Background Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a
CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a …

Plasmablastic lymphoma (PBL) is recognized by the World Health Organization as a very
aggressive subtype of non-Hodgkin lymphoma. It was initially described in the setting of …

Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated
with immunodeficiency, characterized by uncertain treatment approaches and an …

BLOOD RESEARCH Page 1 This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) …

Plasmablastic neoplasms encompass several entities including plasmablastic lymphoma,
plasmablastic plasmacytoma/multiple myeloma, primary effusion lymphoma and its …

Plasmablastic lymphoma (PBL) is a rare and hard to treat disease. With current standard
chemotherapeutic regimens, PBL is associated with a median overall survival of 12–15 …

Plasmablastic lymphoma (PBL) is an aggressive subtype of non‐Hodgkin's lymphoma
(NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) …

Plasmablastic lymphoma (PBL) is a CD20-negative large B-cell lymphoma with a
plasmacytic phenotype and a dismal prognosis, which has been defined as a distinct entity …

This two-part review aims to present a current and comprehensive understanding of the
diagnosis and management of plasmablastic lymphoma. The first section, as presented in …